Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions
Open Forum Infectious Diseases · 30.06.2025 · 12 (7)
DOI: 10.1093/ofid/ofaf368 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 03.07.2025. Verfasst von Anna Maria Geretti und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Cabotegravir plus rilpivirine long-acting (CAB + RPV-LA) injectable therapy marks a major milestone in HIV care, offering an efficacious, well-tolerated alternative to daily oral antiretroviral treatment. This article reviews data from pivotal trials and observational studies of CAB + RPV-LA, addressing emerging questions and highlighting key research priorities. We examine factors influencing virological outcomes, including issues related to HIV subtype, archived drug resistance, body mass index, and pharmacokinetics, and discuss challenges related to hepatitis B virus immunity and infection, pregnancy, and adherence. We outline strategies to address barriers to implementation, advocating for a tailored approach to maximize the potential of CAB + RPV-LA in improving outcomes across diverse populations with HIV.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
- Department of Infection, Royal Free London NHS Foundation Trust-North Mid, London, UK.
- School of Immunity & Microbial Sciences, King's College London, London, UK.
- St Stephens and Department of Infectious Diseases, Chelsea and Westminster Hospital and Imperial College London, London, UK.
- Unit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy.
- PZB Aachen, Laboratory Knechten, Aachen, Germany.
ORCID-Profile: Anna Maria Geretti, Stefano Bonora, Federico Garcia, Jade Ghosn, Perpetua Gomes, Thibault Mesplède, Kyle Ring, Caroline Solas, Eva Wolf, Chloe Orkin
Zitieren
APA
Geretti, A. M., Boffito, M., Bonora, S., Braun, P., Charpentier, C., Garcia, F., Ghosn, J., Gomes, P., Marcelin, A. G., Mesplède, T., Parczewski, M., Ring, K., Santoro, M. M., Solas, C., Wolf, E., & Orkin, C. (2025). Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases, 12(7). https://doi.org/10.1093/ofid/ofaf368
Vancouver
Geretti AM, Boffito M, Bonora S, Braun P, Charpentier C, Garcia F, et al. Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions. Open Forum Infectious Diseases. 2025;12(7). doi:10.1093/ofid/ofaf368
BibTeX
@article{Geretti2025,
author = {Geretti, Anna Maria and Boffito, Marta and Bonora, Stefano and Braun, Patrick and Charpentier, Charlotte and Garcia, Federico and Ghosn, Jade and Gomes, Perpetua and Marcelin, Anne-Geneviève and Mesplède, Thibault and Parczewski, Milosz and Ring, Kyle and Santoro, Maria Mercedes and Solas, Caroline and Wolf, Eva and Orkin, Chloe},
title = {Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions},
journal = {Open Forum Infectious Diseases},
year = {2025},
volume = {12},
number = {7},
doi = {10.1093/ofid/ofaf368}
}
EUVIMED